Apellis Pharmaceuticals Inc (NAS:APLS)
$ 41.605 1.925 (4.85%) Market Cap: 5.05 Bil Enterprise Value: 4.60 Bil PE Ratio: 0 PB Ratio: 18.91 GF Score: 38/100

Q1 2021 Apellis Pharmaceuticals Inc Earnings Call Transcript

Apr 28, 2021 / 08:30PM GMT
Release Date Price: $45.3 (-0.33%)
Operator

Good afternoon. My name is Sara, and I will be your conference operator today. At this time, I would like to welcome everyone to the Apellis Pharmaceuticals First Quarter 2021 Financial Results Conference Call. Today's call is being recorded, and a replay will be available at apellis.com.

I would now like to turn the call over to Tracy Vineis, Vice President of Communications at Apellis.

Tracy Vineis
Apellis Pharmaceuticals, Inc. - VP of Corporate Affairs

Good afternoon, and thank you for joining us to discuss Apellis' first quarter 2021 financial results. With me on the call are Co-Founder and Chief Executive Officer; Dr. Cedric Francois; Chief Medical Officer, Dr. Federico Grossi; Chief Commercial Officer, Adam Townsend; and Chief Financial Officer, Timothy Sullivan.

Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot